Bristol-Myers profit slightly tops Wall Street view on blood thinner sales

Bristol-Myers profit slightly tops Wall Street view on blood thinner sales

U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for US$74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis.

FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headqu
FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headquarters in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau/File Photo

NEW YORK: U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for US$74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis.

Net earnings in the quarter rose to US$1.71 billion, or US$1.04 a share, from US$1.49 billion, or 91 cents a share, a year earlier.

Excluding one-time items, the company said it earned US$1.10 a share. That beat the average analyst estimate by a penny, according to IBES data from Refinitiv.

Bristol-Myers said it still expects full-year adjusted earnings of US$4.10 to US$4.20 per share.

Revenue in the quarter was US$5.92 billion, exceeding analysts' estimates of US$5.75 billion.

That difference is largely due to Eliquis, which Bristol shares with Pfizer Inc. Sales of the drug used to prevent blood clots that can cause strokes jumped 28 percent from last year to US$1.93 billion. Analysts had expected US$1.82 billion from the drug in the quarter.

Sales of cancer immunotherapy Opdivo were in line with Wall Street expectations at US$1.8 billion, up 19 percent from a year ago but basically flat compared with the previous quarter.

Bristol-Myers pioneered cancer immunotherapy with its first such drug Yervoy and later Opdivo. But Merck & Co's rival treatment Keytruda has taken a dominant position in lung cancer - the most lucrative oncology market - taking a toll on Bristol-Myers shares.

Some analysts and investors have suggested that one reason Bristol launched its bid for Celgene was over concerns about Opdivo's growth after losing ground to Merck.

Bristol said it still expects the deal to close in the third quarter, after its shareholders voted to approve the deal earlier this month despite a campaign by activist hedge fund Starboard Value LP to scuttle it.

The company announced in early January that it planned to buy Celgene in a cash and stock transaction to bring together companies that specialize in oncology and cardiovascular drugs in what would be the largest pharmaceutical industry merger ever.

The New York-based drugmaker has said the combined company will have six drugs with expected near-term launches - five from the Celgene pipeline - representing over US$15 billion in annual revenue potential, as well as strong early-stage experimental assets.

Shares of Bristol-Myers closed at US$44.62 on the New York Stock Exchange on Wednesday. They are off by about a third since October, when shares dropped due to setbacks for Opdivo in lung cancer.

(Reporting by Michael Erman; Editing by Bill Berkrot)

Source: Reuters

Bookmark